Table 1 Demographic and disease characteristics at baseline of patients with ankylosing spondylitis (AS) and a history of anterior uveitis (AU)
All patients (n = 1250)History of AU* (n = 274)Recent history of AU† (n = 106)Symptomatic AU at baseline (n = 28)Chronic AU‡ (n = 43)
Chronic uveitis, %3162536100
Male, %7170748272
Age, years, mean (SD)43.6 (11.4)45.6 (10.6)44.0 (10.0)46.1 (13.0)44.4 (9.9)
AS duration, years, mean (SD)11.0 (9.8)14.8 (10.6)13.4 (9.3)14.8 (8.4)15.1 (9.2)
Advanced AS§, %2731314126
Time since onset of uveitis, years, mean (SD)NA9.9 (8.9)6.6 (8.8)7.4 (8.4)9.4 (7.9)
HLA-B27 positive, %8291898290
BASDAI, mean (SD)6.3 (1.4)6.3 (1.4)6.5 (1.4)6.2 (1.7)6.6 (1.5)
BASFI, mean (SD)5.4 (2.2)5.2 (2.3)5.0 (2.5)5.0 (2.8)5.2 (2.5)
CRP, mg/dl, mean (SD)2.0 (2.4)2.4 (2.8)2.8 (3.6)4.1 (4.9)2.6 (3.0)
Treatment with DMARDs, %2628193226
    Treatment with sulfasalazine, %121392512
Oral NSAIDs, %7479787184
Oral glucocorticoids, %141391416
Previous etanercept and/or infliximab treatment, %2623262935
  • *History of AU, history of at least one AU flare anytime. †Recent history of AU, history of at least one AU flare in the past year. ‡Chronic uveitis refers to persistent AU flares of at least 3-month duration and with relapse within less than 3 months according to the Standardization of Uveitis Nomenclature Working Group.6 §Advanced AS, radiographically involvement of at least 50% of the spine in >2 segments.28

  • BASDAI, Bath AS Disease Activity Index; BASFI, Bath AS Functional Index; CRP, C-reactive protein; DMARDs, disease-modifying antirheumatic drugs; NA, not applicable; NSAIDs, non-steroidal anti-inflammatory drugs.